Shane M. Devine

Shane M. Devine

Auto-generated profile, based on publicly available information

Shane M. Devine

Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SDShane M. Devine
Shane M. Devine
MMMark D. Mulcair
Mark D. Mulcair
CDCael O. Debono
Cael O. Debono
ELEleanor W. W. Leung
Eleanor W. W. Leung
JNJ. Willem M. Nissink
J. Willem M. Nissink
MSMartin J. Scanlon
Martin J. Scanlon

6 August 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TATrent D. Ashton
Trent D. Ashton
SDShane M. Devine
Shane M. Devine
JMJörg J. Möhrle
Jörg J. Möhrle
BLBenoît Laleu
Benoît Laleu
JBJeremy N. Burrows
Jeremy N. Burrows
Brad E. SleebsBrad E. Sleebs
Brad E. Sleebs

1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PKPeter Keov
Peter Keov
LLLaura López
Laura López
SDShane M. Devine
Shane M. Devine
CVCeline Valant
Celine Valant
JLJ. Lane
J. Lane
ACArthur Christopoulos
Arthur Christopoulos
TBPB and 77-LH-28-1 are selective agonists of the M1 muscarinic acetylcholine receptor (mAChR) that may gain their selectivity through a bitopic mechanism, interacting concomitantly with the orthosteric site and part of an allosteric site. The current study combined site-directed mutagenesis, analytical pharmacology,and molecular modeling to gain further insights into the structural basis underlying binding and signaling by these agonists. Mutations within the orthosteric binding site caused similar reductions in affinity and signaling efficacy for both selective and prototypical orthosteric ligands. In contrast, the mutation of residues within transmembrane helix (TM) 2 and the second extracellular loop (ECL2) discriminated between the different classes of ligand. In particular, ECL2 appears to be involved in the selective binding of bitopic ligands and in coordinating biased agonism between intracellular calcium mobilization and ERK1/2 phosphorylation. Molecular modeling of the interaction between TBPB and the M1 mAChR revealed a binding pose predicted to extend from the orthosteric site up toward a putative allosteric site bordered by TM2, TM3, and TM7, thus consistent with a bitopic mode of binding. Overall, these findings provide valuable structural and mechanistic insights into bitopic ligand actions and receptor activation and support a role for ECL2 in dictating the active states that can be adopted by a G protein-coupled receptor. This may enable greater selective ligand design and development for mAChRs and facilitate improved identification of bitopic ligands.

17 February 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CVCeline Valant
Celine Valant
LALuigi Aurelio
Luigi Aurelio
SDShane M. Devine
Shane M. Devine
TATrent Ashton
Trent Ashton
JWJonathan M. White
Jonathan M. White
PSPeter J. Scammells
Peter J. Scammells

14 November 2014 in Biochemistry
Verified
Journal Article
Open access
SLSan Sui Lim
San Sui Lim
WYWei Yang
Wei Yang
BKBankala Krishnarjuna
Bankala Krishnarjuna
KSKomagal Kannan Sivaraman
Komagal Kannan Sivaraman
ICIndu Chandrashekaran
Indu Chandrashekaran
SMSheena McGowan
Sheena McGowan
Apical membrane antigen 1 (AMA1) interacts with RON2 to form a protein complex that plays a key role in the invasion of host cells by malaria parasites. Blocking this protein–protein interaction represents a potential route to controlling malaria and related parasitic diseases, but the polymorphic nature of AMA1 has proven to be a major challenge to vaccine-induced antibodies and peptide inhibitors exerting strain-transcending inhibitory effects. Here we present the X-ray crystal structure of AMA1 domains I and II from Plasmodium falciparum strain FVO. We compare our new structure to those of AMA1 from P. falciparum 3D7 and Plasmodium vivax. A combination of normalized B factor analysis and computational methods has been used to investigate the flexibility of the domain I loops and how this correlates with their roles in determining the strain specificity of human antibody responses and inhibitory peptides. We also investigated the domain II loop, a key region involved in inhibitor binding, by comparison of multiple AMA1 crystal structures. Collectively, these results provide valuable insights that should contribute to the design of strain-transcending agents targeting P. falciparum AMA1.

1 December 2010 in Tetrahedron Letters
Verified
Journal Article
Closed access
AGAnnelies Goeminne
Annelies Goeminne
PSPeter J. Scammells
Peter J. Scammells
SDShane M. Devine
Shane M. Devine
BFBernard L. Flynn
Bernard L. Flynn